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Abstract 
The pathophysiology of multiple sclerosis (MS) is complex with the presence of inflammation 
and neurodegeneration in all stages of the disease. The disease course, treatment response and 
outcome are highly variable in MS. There is a need for reliable biomarkers reflecting different 
parts of the pathophysiology of MS that may improve the decision-making between various treat-
ment options. The aim of the thesis was to investigate the influence of different therapies on bi-
omarker levels in cerebrospinal fluid (CSF) and blood, explore the relationships between inflam-
matory and degenerative biomarkers, their diagnostic value and the value of measuring brain at-
rophy, i.e. brain parenchymal fraction (BPF) and the thinning of retinal nerve fibre layer (RNFL) 
to detect signs of early degeneration. 
In study I, treatment with natalizumab reduced 24S-hydroxycholesterol concentrations in CSF 
and serum and 27-hydroxycholesterol concentrations in CSF. 
In study II, relapsing-remitting MS patients had higher levels of neurofilament light (NFL), 
CXCL13, chitinase-3-like-1 (CHI3L1), and chitotriosidase 1 (CHIT1) than controls. Subgroup anal-
ysis revealed higher levels of NFL, CXCL13 and CHIT1 in patients treated with first-line therapy 
compared to second-line therapy. NFL and CHIT1 levels correlated with relapse status, and NFL 
and CXCL13 levels correlated with the formation of new lesions on MRI. 
In study III, the levels of NFL, CXCL13, and CHI3L1 decreased after treatment with fin-
golimod. 
In study IV, high correlation between serum and CSF NFL was found. Serum concentrations 
of NFL were significantly higher in MS patients than in healthy controls and treatment reduced 
serum NFL levels. Patients with relapse or with radiologic activity had higher serum NFL levels 
than those in remission or those without new lesions on MRI. 
In study V, all phenotypes of MS had increased NFL compared to HC. Increased glial fibrillary 
acidic protein (GFAP), lower BPF and RNFL were associated with progressive MS but not with 
other phenotypes of MS. Lower BPF and RNFL, indicating neurodegeneration, were associated 
with longer disease duration. 
We showed that CSF biomarkers that represent different parts of the pathophysiology of MS 
were related to both clinical and radiological measures. The correlation between neurodegenera-
tive and inflammatory biomarkers, and the lack of signs of neurodegeneration in the earliest 
phases of relapsing-remitting MS, confirms the hypothesis regarding inflammatory-induced de-
generation. The most important finding is that the blood-based biomarker NFL can reflect the 
disease activity and treatment efficacy. This finding is based on a large set of paired serum and 
CSF samples from a real-life cohort of patients across a wide clinical and therapeutic spectrum. 
Therefore, repeated serum NFL measurements may represent new possibilities for the monitoring 
of MS. 
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